Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Table 5 Clinical and economic outcomes for CAZ-AVI sequence vs. Meropenem sequence, discounted by 3%

Outcomes	CAZ-AVI Sequence^a	Meropenem Sequence^b
% of patients with cure	92.98%	90.24%
% of patients died in hospital	5.04%	5.68%
% of patients with AE	6.14%	5.74%
Average days in hospital	12.94	14.18
LYs	4.410	4.381
QALYs	4.019	3.960
Drug costs	€ 2943	€ 818
Hospitalisation costs	€ 11,262	€ 12,453
SAE costs	€ 186	€ 174
Recurrence costs	€ 0	€ 22
Total costs	€ 14,391	€ 13,467
Incremental cost per QALY gained	€ 15,574

AE = adverse event; CAZ-AVI = ceftazidime-avibactam; LY = life year; QALY = quality-adjusted life year; SAE = serious adverse event.
^aCAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem
^bMeropenem, followed by colistin + tigecycline + high-dose meropenem

ISSN: 2047-2994